Pneumonia Therapeutics Market - Infographics- AMR

The global pneumonia therapeutics market size is projected to reach $25,546.8 million by 2030, registering a CAGR of 8.5% from 2021 to 2030.

PORTLAND, OREGON, UNITED STATES, April 27, 2023 /EINPresswire.com/ -- Pneumonia is a serious respiratory infection that can be caused by bacteria, viruses, or fungi. It is a leading cause of death worldwide, especially in children under the age of five and in the elderly. Fortunately, there are effective therapeutics available to treat pneumonia, including antibiotics, antivirals, and antifungal medications, depending on the underlying cause. Treatment also involves managing symptoms, such as fever and cough, and providing supportive care, such as oxygen therapy. It is important to seek medical attention promptly if you suspect you or a loved one may have pneumonia, as early treatment can improve outcomes and prevent complications.

𝐑𝐞𝐪𝐮𝐞𝐬𝐭 𝐑𝐞𝐩𝐨𝐫𝐭 𝐒𝐚𝐦𝐩𝐥𝐞- https://www.alliedmarketresearch.com/request-sample/11595

The global pneumonia therapeutics market size was valued at $12,293.9 million in 2020, and is projected to reach $25,546.8 million by 2030, registering a CAGR of 8.5% from 2021 to 2030.

• CAGR: 8.5%
• Current Market Size: USD 12.29 Billion
• Forecast Growing Region: APAC
• Largest Market: North America
• Projection Time: 2021- 2030
• Base Year: 2021

Surge in prevalence of pneumonia, rise in geriatric population with weaker immune systems, increase in incidence and spending for community-acquired pneumonia, and rise in number of product launches drive the growth of the global pneumonia therapeutics market. However, high price of pneumonia therapeutics restrains the market to some extent. On the other hand, outbreak of novel viruses attacking respiratory system presents new opportunities in the upcoming years.

𝐏𝐫𝐨𝐜𝐮𝐫𝐞 𝐂𝐨𝐦𝐩𝐥𝐞𝐭𝐞 𝐑𝐞𝐩𝐨𝐫𝐭 (208 𝐏𝐚𝐠𝐞𝐬 𝐏𝐃𝐅 𝐰𝐢𝐭𝐡 𝐈𝐧𝐬𝐢𝐠𝐡𝐭𝐬, 𝐂𝐡𝐚𝐫𝐭𝐬, 𝐓𝐚𝐛𝐥𝐞𝐬, 𝐚𝐧𝐝 𝐅𝐢𝐠𝐮𝐫𝐞𝐬) @ https://www.alliedmarketresearch.com/pneumonia-therapeutics-market/purchase-options

𝐂𝐎𝐕𝐈𝐃-19 𝐬𝐜𝐞𝐧𝐚𝐫𝐢𝐨:
• The outbreak of the COVID-19 pandemic has positively impacted the pneumonia therapeutics market, owing to declaration by WHO that people suffering from COVID-19 is highly susceptible to pneumonia.
• Moreover, surge in R&D for the treatment of COVID-19 associated pneumonia has generated high revenue.
• However, dearth of workforce as well as resource limitations due to COVID-19 are expected to negatively impact the growth of the industry in the forecast period.

Based on therapeutics, the prevention vaccines segment held the highest market share in 2020, holding more than two-thirds of the total market share, and is expected to continue its leadership status during the forecast period. However, the treatment drugs segment is estimated to register the highest CAGR of 9.6% from 2021 to 2030.

𝐃𝐨 𝐏𝐮𝐫𝐜𝐡𝐚𝐬𝐞 𝐄𝐧𝐪𝐮𝐢𝐫𝐲 - https://www.alliedmarketresearch.com/purchase-enquiry/11595

𝐊𝐞𝐲 𝐏𝐥𝐚𝐲𝐞𝐫𝐬 –
• Abbott Laboratories
• Bayer AG
• Eli Lilly & Company
• Glaxosmithkline PLC
• Lupin Pharmaceuticals, Inc.
• Merck KGAA
• Novartis AG
• Pfizer, Inc.
• Sanofi S.A.
• Teva Pharmaceuticals Industries Limited

𝐎𝐭𝐡𝐞𝐫 𝐓𝐫𝐞𝐧𝐝𝐢𝐧𝐠 𝐑𝐞𝐩𝐨𝐫𝐭𝐬-
𝐂𝐎𝐏𝐃 𝐚𝐧𝐝 𝐀𝐬𝐭𝐡𝐦𝐚 𝐃𝐢𝐚𝐠𝐧𝐨𝐭𝐢𝐜 𝐚𝐧𝐝 𝐌𝐨𝐧𝐢𝐭𝐨𝐫𝐢𝐧𝐠 𝐃𝐞𝐯𝐢𝐜𝐞 𝐌𝐚𝐫𝐤𝐞𝐭- https://www.alliedmarketresearch.com/copd-and-asthma-diagnostic-and-monitoring-devices-market-A10567
𝐁𝐨𝐝𝐲 𝐅𝐚𝐭 𝐑𝐞𝐝𝐮𝐜𝐭𝐢𝐨𝐧 𝐌𝐚𝐫𝐤𝐞t-https://www.alliedmarketresearch.com/body-fat-reduction-market-A10916
𝐏𝐡𝐚𝐫𝐦𝐚𝐜𝐞𝐮𝐭𝐢𝐜𝐚𝐥 𝐒𝐮𝐩𝐩𝐨𝐬𝐢𝐭𝐨𝐫𝐢𝐞𝐬 𝐌𝐚𝐫𝐤𝐞𝐭-https://www.alliedmarketresearch.com/pharmaceutical-suppositories-market-A12350

David Correa
Allied Analytics LLP
+1-800-792-5285
email us here

Legal Disclaimer:

EIN Presswire provides this news content "as is" without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.